Kymera Therapeutics (KYMR) Assets Average (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Assets Average data on file, last reported at $1.7 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.7 billion, up 79.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 79.92% YoY), and the FY2025 annual result was $1.4 billion, up 75.11% from the prior year.
• Assets Average grew to $1.7 billion in Q1 2026 per KYMR's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.7 billion in Q1 2026 and troughed at $543.2 million in Q2 2022.
• A 5-year average of $846.5 million and a median of $722.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2026: Assets Average declined 9.14% in 2023, then jumped 79.92% in 2026.
• A 5-year view of Assets Average shows it stood at $620.8 million in 2022, then retreated by 9.14% to $564.1 million in 2023, then surged by 78.42% to $1.0 billion in 2024, then surged by 41.33% to $1.4 billion in 2025, then increased by 19.93% to $1.7 billion in 2026.
• Business Quant data shows KYMR's Assets Average at $1.7 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.1 billion in Q3 2025.